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SUMMARY
Two mimotopes of Leishmania infantum identiﬁed by phage display were evaluated as vaccine candidates in BALB/c mice
against Leishmania amazonensis infection. The epitope-based immunogens, namely B10 and C01, presented as phage-
fused peptides; were used without association of a Th1 adjuvant, and they were administered isolated or in combination
into animals. Both clones showed a speciﬁc production of interferon-gamma (IFN-γ), interleukin-12 (IL-12) and granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) after in vitro spleen cells stimulation, and they were able to induce
a partial protection against infection. Signiﬁcant reductions of parasite load in the infected footpads, liver, spleen, bone
marrow and paws’ draining lymph nodes were observed in the immunized mice, in comparison with the control groups
(saline, saponin, wild-type and non-relevant clones). Protection was associated with an IL-12-dependent production of
IFN-γ, mediated mainly by CD8+ T cells, against parasite proteins. Protected mice also presented low levels of IL-4
and IL-10, as well as increased levels of parasite-speciﬁc IgG2a antibodies. The association of both clones resulted in
an improved protection in relation to their individual use. More importantly, the absence of adjuvant did not diminish
the cross-protective eﬃcacy against Leishmania spp. infection. This study describes for the ﬁrst time two epitope-based
immunogens selected by phage display technology against L. infantum infected dogs sera, which induced a partial protec-
tion in BALB/c mice infected with L. amazonensis.
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INTRODUCTION
Leishmaniasis presents a highmorbidity andmortality
throughout the world, where about 350million people
in 98 countries are at risk of contracting the infection
(WHO, 2010). Moreover, approximately 1·0–1·5
million new cases of tegumentary leishmaniasis (TL)
and 200 000–500 000 new cases of visceral leishmania-
sis (VL) have been registered annually (Alvar et al.
2012). Several geographical regions are endemic for
diﬀerent Leishmania spp. species, being this the case
of the South America, where the disease is caused by
at least eight diﬀerent species of the parasites
(Grimaldi and Tesh, 1993; Coelho et al. 2003;
Reithinger et al. 2007).Among them,Leishmania ama-
zonensis, presents particular importance, since it is able
to cause human disease (Garcez et al. 2002), as well as a
broad spectrum of clinical manifestations, from cuta-
neous to VL (Barral et al. 1991). The treatment of
thedisease ishampereddue to the side eﬀects registered
in the patients, by increased parasite resistance and the
high cost of conventional drugs (Croft and Coombs,
2003; Minodier and Parola, 2007). Recently, Bacon
et al. (2013) evaluated the potential economic value of
a cutaneous leishmaniasis (CL) vaccine in endemic
countries localized in the Americas, and the study pre-
dicted that if a vaccine could provide at least 5 years of
protection, then this would be less costly. Therefore,
the development of improved strategies to prevent
* Corresponding author. Laboratório de Biotecnologia
Aplicada ao Estudo das Leishmanioses, Universidade
Federal de Minas Gerais, Avenida Antônio Carlos 6627,
31·270-901 Belo Horizonte, Minas Gerais, Brazil.
E-mail: eduardoferrazcoelho@yahoo.com.br
1335
Parasitology (2015), 142, 1335–1347. © Cambridge University Press 2015
doi:10.1017/S0031182015000724
leishmaniasis could be considered a priority (Costa
et al. 2011; Coelho et al. 2012).
The evidence of life-long immunity against infec-
tion with some Leishmania spp. species has inspired
the development of prophylactic vaccination
models, but few have progressed beyond the experi-
mental stage (Fernandes et al. 2008; Chávez-
Fumagalli et al. 2010; Modabber, 2010; Das and
Ali, 2012; Ramírez et al. 2013, 2014; Costa et al.
2014). Using murine models, it has been showed
that an important challenge for the development of
an eﬀective vaccine is to ﬁnd a formulation able to
induce a Th1-type immunity, based on the produc-
tion of cytokines, such as IFN-γ, IL-12 and GM-
CSF, produced by CD4+ and/or CD8+ T cells; as
well as by controlling the disease-associated, IL-4-
mediated, humoral response (mainly in TL
models) and IL-10 deactivating response (Afonso
and Scott, 1993; Noben-Trauth et al. 2003). From
these experimental models, vaccine candidates such
as whole parasite (Mizbani et al. 2009; Dey et al.
2013), parasite fractions (Rosa et al. 2007; Iborra
et al. 2008; Chávez-Fumagalli et al. 2010), recom-
binant proteins (Coelho et al. 2003; Fernandes
et al. 2008; Martins et al. 2013), poly-proteins
(Bertholet et al. 2009; Goto et al. 2011), DNA-
based vaccine (Zanin et al. 2007; Carrión et al.
2008) and synthetic peptides (Spitzer et al. 1999;
Basu et al. 2007), have been shown to be immune
stimulatory, and induce variable degrees of protec-
tion against some Leishmania spp. species. There
are two commercial vaccines against CVL available
at Brazil, Leishmune® (Borja-Cabrera et al. 2008)
and Leish-Tec® (Fernandes et al. 2008), which are
formulated with the nucleoside hydrolase and A2
proteins, respectively, associated with saponin, as
adjuvant. In Europe, there is the CaniLeish®
(Moreno et al. 2012), which is based on the
LiESP/QA-21 association. Protein-based vaccines,
although oﬀering considerable advantages in terms
of safety and production’ costs, usually necessity of
association of adjuvants to be eﬀective (Cerpa-Cruz
et al. 2013). Notwithstanding, the adjuvants regula-
tion for human use is far more rigorous than those
applied to veterinary vaccines. In addition to pre-
clinical studies on the adjuvant itself, the combined
antigen–adjuvant formulation also requires toxico-
logical evaluation for entering phase 1 clinical trials
(Goldenthal et al. 1993). Amongst the biggest regu-
latory hurdles is the required population size that
needs to be tested to prove eﬃcacy and particularly
safety of a new adjuvant or vaccine.
Therefore, eﬀective vaccine formulations that do
not have adjuvants will have one less safety and regu-
latory hurdle in comparison with vaccines that
include adjuvants (Bazan et al. 2012). An interesting
approach towards the discovery of new products to
be evaluated in biotechnological applications has
been based on phage display technology (Clark and
March, 2004). This technology is focused on DNA
recombination, resulting in the expression of
foreign peptide variants, namely mimotopes, on
the outer surface of phage clones (Smith and
Petrenko, 1997). Using an in vitro selection
process, based on binding aﬃnity, so-called bio-
panning cycles; these mimotopes (that correspond
to peptides that mimic linear, discontinuous and
even non-peptide epitopes) exposed on surface of
phages are selected, analysed by DNA sequencing
and identiﬁed (Barbas et al. 2001; Wang and Yu,
2004). Phage display has been used to select mimo-
topes to be applied as vaccine candidates against
cysticercosis (Manoutcharian et al. 2004), trichinel-
losis (Gu et al. 2008), VL (Costa et al. 2014) and
Alzheimer’s disease (Frenkel et al. 2000); as well as
therapeutic agents (Manoutcharian et al. 2001).
Recently, our group reported the use of this tech-
nology to identify mimotopes that were highly react-
ive with sera from 100% of dogs infected by
L. infantum. Two clones, B10 and C01, were
selected and evaluated in vaccination experiments
in BALB/c mice. Both immunogens, when asso-
ciated with saponin, were able to induce a Th1
immune response before infection, which was
based on the production of high levels of IFN-γ,
IL-12 and GM-CSF; as well as low levels of IL-4
and IL-10 and, after challenge, they were protective
against infection (Costa et al. 2014).
In the present study, these two phage clones were
further tested as cross-protective immunogens
against L. amazonensis infection, with and without
added adjuvants, in order to evaluate the inherent
immune-enhancing potential of the phage capsid, as
has been previously described (García et al. 2005;
Manoutcharian, 2005). The partial cross-protection
induced by both clones against infection was demon-
strated with and without saponin, suggesting that
elicitation of the protective Th1 immune response
was phage-dependent. Thus, we present evidence
that a simple vaccine formulation composed of the
combination of two epitope-based immunogens




Female BALB/c mice (8 weeks of age) were obtained
from the breeding facilities of the Department of
Biochemistry and Immunology, Institute of Biological
Sciences (ICB), Federal University of Minas Gerais
(UFMG); and were maintained under speciﬁc patho-
gen-free conditions. Experiments were performed in
compliance with the Brazilian Guidelines for Animal
Care (Law number 11 794, 2008), and under the ap-
proval of the Ethics Committee on the Handling of
Research Animals from the UFMG, protocol number
043/2011.
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Parasites
Experiments were carried out using theL. amazonensis
(IFLA/BR/1967/PH-8) strain. Parasites were grown
at 24 °C in Schneider’s medium (Sigma-Aldrich,
St. Louis, MO, USA), which was supplemented
with 10% heat-inactivated fetal bovine serum (FBS;
Sigma-Aldrich), 20 mM L-glutamine, 200 U mL−1
penicillin and 100 μg mL−1 streptomycin, at pH 7·4.
The soluble Leishmania antigenic (SLA) extract was
prepared from stationary-phase promastigotes, as
described (Coelho et al. 2003). Brieﬂy, 1 × 109 pro-
mastigotes of L. amazonensis per mL, in a volume of
5 mL, were washed three times in 5 mL of cold
sterile phosphate-buﬀered saline (PBS). After seven
cycles of freezing (−196 °C) and thawing (+37 °C),
the suspension was centrifuged at 8000 g for 20 min
at 4 °C, and the supernatant containing SLA was col-
lected in 500 μL aliquots and stored at −80 °C, until
use. The protein concentration was estimated by the
Bradford method (Bradford, 1976).
Selection of the phage clones
The technical procedures used to select the B10 and
C01 phage clones were performed as previously
described (Costa et al. 2014).
Immunization and challenge infection
Seven groups of 8 BALB/c mice were inoculated into
the left hind footpadwithdiluent (PBS); or immunized
with 1 × 1011 non-adjuvanted bacteriophages of the
parent wild-type clone (WTP), a non-relevant phage
(NRP), the B10 clone, the C01 clone or a combination
of the B10 and C01 clones (5 × 1010 phages, each) in
equal proportions; or with 25 μg of saponin adjuvant
(Quillaja saponaria bark saponin; Sigma 178 Aldrich)
mixed with the combined B10 and C01 clones. Three
doses were administered at 2-week intervals. Four
weeks after the last immunization, animals (n= 4, per
group) were euthanized to analyse the immune re-
sponse elicited by vaccination. At the same time, the
remaining animals were infected subcutaneously in
their right hind footpad with 1 × 106 stationary-phase
promastigotes of L. amazonensis. The course of the
disease was monitored at weekly intervals by measur-
ing footpad thickness with a metric calliper, and
expressed as the increase in thickness of the infected
footpad compared with the uninfected footpad. Ten
weeks post-challenge, animals were euthanized and
their sera samples, infected footpads and some organs
were harvested for immunological analysis andparasite
quantiﬁcation. Experiments were repeated twice and
presented similar results.
Estimation of parasite load
The infected footpad, liver, spleen, bone marrow
(BM) and infected paws’ draining lymph nodes
(dLN) were collected for parasite quantiﬁcation,
using a limiting-dilution technique (Coelho et al.
2003). Brieﬂy, tissue and organs were weighed and
homogenized using a glass tissue grinder in sterile
PBS. Tissue debris were removed by centrifugation
at 150 g, and cells were concentrated by centrifuga-
tion at 2000 g. Pellets were resuspended in 1 mL of
Schneider’s insect medium supplemented with
20% FBS. Two hundred and twenty microlitres
were plated onto 96-well ﬂat-bottom microtitre
plates (Nunc), and diluted in log-fold serial dilutions
using the supplemented Schneider’s medium, to a
10−1–10−12 dilution. Each sample was plated in trip-
licate and read 7 days after the beginning of the cul-
tures, at 24 °C. Pipette tips were discarded after each
dilution to avoid carrying adhered parasites from one
well to another. Results are expressed as the negative
log of the titre (i.e. the dilution corresponding to the
last positive well) adjusted per microgram of tissue.
Cytokine response and nitric oxide (NO) production
Spleen cells cultures and cytokine assays were per-
formed before infection and at 10th week after
challenge, as described (Coelho et al. 2003).
Brieﬂy, single-cell suspensions from spleen tissue
were plated in duplicate in 24-well plates (Nunc),
at 5 × 106 cells mL−1. Cells were incubated in
RPMI 1640 medium (negative control), which was
supplemented with 10% FBS, 20 mM L-glutamine,
200 U mL−1 penicillin, and 100 μg mL−1 strepto-
mycin, at pH 7·4; or separately stimulated with indi-
vidual B10, C01, WTP or NRP clones (1 × 1011
phages, each one) or with SLA L. amazonensis (25
μg mL−1); for 48 h at 37 °C in 5% CO2. IFN-γ,
IL-4, IL-10, IL-12 and GM-CSF levels were deter-
mined in the culture supernatants, using commercial
kits (Pharmingen), according to manufacturer’s
instructions. In order to block IL-12, CD4+ and
CD8+ mediated T cells cytokine release, spleen
cells of mice vaccinated with B10/C01, added or
not with saponin, and lately infected with L. amazo-
nensis, were in vitro stimulated with SLA L. amazo-
nensis (25 μg mL−1), and incubated in the presence
of 5 μg mL−1 of monoclonal antibodies (mAb)
against mouse IL-12 (C017·8), CD4 (GK 1·5) or
mouse CD8 (53–6·7). Appropriate isotype-matched
controls – rat IgG2a (R35-95) and rat IgG2b (95-
1) – were employed in the assays. Antibodies (no
azide/low endotoxin) were purchased from BD
(Pharmingen).
The NO production was evaluated in all groups, at
10th week after challenge, for which 100 μL of SLA-
stimulated culture supernatants were mixed with an
equal volume of Griess reagent (Sigma). After 30-
min incubation at room temperature, nitrite concen-
tration was calculated using a standard curve of
known concentrations. Data were expressed as
μM per 5 × 106 cells.
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Analysis of the humoral response
The B10- and C01-speciﬁc IgG1 and IgG2a anti-
bodies, as well as SLA L. amazonensis-speciﬁc
IgG1 and IgG2a antibodies were measured by an
enzyme-linked immunosorbent assay (ELISA) tech-
nique. Brieﬂy, previous titration curves were per-
formed to determine the appropriate antigens
concentration and antibodies dilution. Microtitre
immunoassay plates (Bioﬁl®, Belo Horizonte,
Minas Gerais, Brazil) were coated with either B10
or C01 clone (1 × 1010 phages per well) or with
SLA L. amazonensis (1·0 μg per well) diluted in
100 μL coating buﬀer (50 mM carbonate buﬀer, pH
9·6) for 18 h at 4 °C. After incubation, free binding
sites were blocked using 200 μL of TBS-T (50 mM
Tris–HCl pH 7·5, 150 mM NaCl and 0·1% Tween
20) buﬀer containing 5% casein for 1 h at 37 °C.
After having been washing three times using PBS-
T, the plates were incubated with sera samples
diluted 1:100 in TBS-T containing 0·5% casein solu-
tion for 1 h at 37 °C. Then, plates were washed seven
times using TBS-T, and incubated with the perox-
idase-labelled antibodies speciﬁc to mouse IgG1 or
IgG2a isotypes (Sigma-Aldrich) diluted at 1:5000
and 1:10 000, respectively; and incubated for 1 h at
37 °C. Plates were again washed seven more times
with TBS-T, and the reaction was developed
through incubation with 2 mg orto-phenylenedi-
amine, 2 μL H2O2 (30 vol.) and 10 mL citrate-phos-
phate buﬀer (pH 5·0), for 30 min and in the dark.
The reaction was stopped by adding 25 μL H2SO4
2 N, and optical density was read in an ELISA
microplate spectrophotometer (Molecular Devices,
Spectra Max Plus, Concord, Canada), at 492 nm.
Statistical analysis
Results were entered into Microsoft Excel (version
10.0), and analysed using GraphPad Prism™
(version 6.0 for Windows). Results were expressed
by mean ± standard deviation (S.D.) of the groups.
Statistical analysis with the data from vaccinated
and/or infected mice was performed by one-way ana-
lysis of variance (ANOVA), using Tukey’s post-test
for comparisons among groups. Diﬀerences were
considered signiﬁcant with P< 0·05. Data shown in
this study are representative of two independent vac-
cination experiments, which presented similar
results.
RESULTS
Immunogenicity of selected phage clones in BALB/c
mice
Two phage clones (B10 and C01) isolated by their
antigenicity in CVL, and tested as protective
against L. infantum (Costa et al. 2014), were analysed
for their protective role against L. amazonensis
infection. Clones were administered independently
in the absence of any adjuvant and in combination,
in this case, associated or not with saponin. The im-
munogenicity of the clones was evaluated in the
immunized mice 4 weeks after the last vaccine dose
(Fig. 1). Spleen cells’ cultures derived from vacci-
nated mice with the B10 and/or C01 clones signiﬁ-
cantly secreted higher levels of IFN-γ and IL-12
than cells from control groups (WTP, NRP and
saline) after speciﬁc stimuli with each phage clone.
In addition, very low levels of IL-4 and IL-10
were observed in all experimental groups, after
stimulation with speciﬁc clones employed in the vac-
cination regimens (Fig. 1A). Also, spleen cells cul-
tured from the saline group were separately
stimulated with the individual clones; however, no
signiﬁcant cytokines production was observed (data
not shown). The ratios between the IL-12/IL-4
and IL-12/IL-10 levels (Fig. 1B), as well as
between the IFN-γ/IL-4 and IFN-γ/IL-10 levels
(Fig. 1C), were calculated and the results showed
that vaccinated animals with B10, C01, B10/C01
and B10/C01/saponin were able to induce a speciﬁc
Th1 response before infection, when the speciﬁc
phage-stimulus was employed in culture cells. The
association between B10 and C01 clones was able
to increase these cytokines’ ratios. In addition,
when the humoral response was evaluated, mice vac-
cinated with B10 and/or C01 clones presented higher
predominance of the phage-speciﬁc IgG2a isotype in
comparison with the phage-speciﬁc IgG1 levels
(Fig. 1D), corroborating with the higher production
of IFN-γ and lower levels of IL-4 in these vaccinate
animals, representing a typical and speciﬁc Th1
immune response mounted in these vaccinated
animals.
Protective eﬃcacy of the phage clones against
L. amazonensis
The protective eﬀect of immunization of BALB/c
mice with the B10 and C01 clones against L. amazo-
nensis infection was evaluated by measuring lesion
development in infected footpads, as well as by de-
termination of the parasite burden in infected
tissues and some organs of the animals (Fig. 2).
Animals vaccinated with B10, C01, B10/C01 and
B10/C01/saponin presented partial protection and
signiﬁcant reductions in oedema in the infected foot-
pads when compared with control groups (saline,
WTP and NRP). The reduction in the lesion devel-
opment observed in these groups correlated with a 3
mm decrease in the infected footpad swellings, when
compared with control groups (Fig. 2A). No signiﬁ-
cant diﬀerences were observed in lesion develop-
ment among immunized groups with B10, C01,
B10/C01 or B10/C01/saponin, corroborated by the
diminished footpad swellings and parasite burden
in the infected tissue in comparison with the
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control groups (Fig. 2B). Also, vaccinated mice with
B10 and/or C01 phage clones presented signiﬁcant
reductions in the number of parasites in the liver,
spleen, dLN and BM in comparison with control
groups (saline, WTP or NRP) (Fig. 3). On the
other hand, the combination of B10 and C01
clones was able to induce a better protection
against infection, when compared with the use of in-
dividual clones. The employ of saponin as adjuvant
to the B10/C01 vaccine did not induce any signiﬁ-
cant alteration in the vaccine eﬃcacy, when com-
pared with the group of animals immunized with
both clones, but without the association of this
adjuvant.
Cellular response elicited after L. amazonensis
infection
The production of cytokines in the supernatants of
spleen cell cultures stimulated with speciﬁc phages
or SLA L. amazonensis, 10 weeks after infection,
was analysed in order to evaluate the immunological
correlates of protection induced by previous immun-
ization (Fig. 4). The spleen cells derived from mice
vaccinated with B10, C01, B10/C01 or B10/C01/
saponin produced higher levels of phages- and
SLA-speciﬁc IFN-γ, IL-12 and GM-CSF than
did those secreted by spleen cells from control
groups (saline, WTP and NRP). In contrast, the
phages- and SLA-driven production of IL-4 and
IL-10 showed that vaccination with both clones
induced no signiﬁcant production of these cytokines
in the vaccinated and infected animals (Fig. 4A).
The ratios between the IFN-γ/IL-4 and IFN-γ/
IL-10 levels (Fig. 4B), as well as between the IL-
12/IL-4 and IL-12/IL-10 levels (Fig. 4C) obtained
after the SLA L. amazonensis stimulus were calcu-
lated, and showed that vaccinated and infected
animals mounted a typical Th1 immune response
against parasites, which has possibly contributed to
the partial protection observed against the challenge.
The involvement of CD4+ and CD8+ T cells, as
well as the dependence of IL-12 production for the
SLA L. amazonensis-speciﬁc IFN-γ response from
the spleen cells of mice immunized with B10/C01
or B10/C01/saponin, and lately infected with
L. amazonensis, was evaluated (Fig. 5). The IFN-γ
production was signiﬁcantly suppressed using the
Fig. 1. Immune response induced in BALB/c mice by immunization with B10 and/or C01 phage clones. Single cells
suspensions were obtained from the spleen of mice, 4 weeks after the last immunization. Cells were non-stimulated
(negative control), or separately stimulated with the B10, C01, wild-type (WTP) or NRP clones (1 × 1011 phages, each
one), for 48 h at 37 °C in 5% CO2. IFN-γ, IL-12, GM-CSF, IL-4 and IL-10 levels were measured in culture supernatants
by capture ELISA (A). Each bar represents the mean ± S.D. of the diﬀerent groups. The ratios between the IL-12/IL-10
and IL-12/IL-4 levels (B), as well as between the IFN-γ/IL-10 and IFN-γ/IL-4 levels (C); are showed. Also, the ratio
between the levels of speciﬁc phage-IgG2a and IgG1 antibodies were calculated, and are shown (D). (a) indicates
statistically signiﬁcant diﬀerence in relation to the saline group (P < 0·001). (b) indicates statistically signiﬁcant diﬀerence
in relation to the WTP group (P< 0·001). (c) indicates statistically signiﬁcant diﬀerence in relation to the NRP group
(P< 0·001).
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anti-CD8 monoclonal antibody in the spleen cell
cultures in both B10/C01 (Fig. 5A) and B10/C01/
saponin (Fig. 5B) groups. On the other hand, the
addition of anti-CD4 or anti-IL-12 antibodies to
the cultures also decreased the production of this
cytokine when compared with the control cells
culture without treatment; however, this production
proved to be greater than that occurred by use of
anti-CD8+ monoclonal antibody (Fig. 5).
Humoral response and nitrite production after infection
Evaluating the humoral response induced after chal-
lenge, it was also possible to observe that mice vacci-
nated with B10, C01, B10/C01 or B10/C01/saponin
and infected presented a signiﬁcant predominance
of SLA L. amazonensis-speciﬁc IgG2a antibodies,
which was signiﬁcantly higher than the observed
SLA-speciﬁc IgG1 levels. The ratio between
IgG2a and IgG1 levels (Fig. 6A) corroborated with
the Th1 proﬁle found in the vaccinated and pro-
tected animals.
In an attempt to evaluate the inﬂuence of the
phage clones on the L. amazonensis speciﬁc killing
Fig. 2. Protection of BALB/c mice vaccinated with B10
and C01 phage clones against Leishmania amazonensis
infection. Mice were inoculated with saline or immunized
with wild-type (WTP), non-relevant (NRP), B10 or C01
clones (1 × 1011 phages, each one), or with the association
between B10 and C01 clones (5 × 1010 phages, each), with
or without 25 μg of saponin (Quillaja saponaria bark
saponin; Sigma-Aldrich). Three doses were administered
at 2-week intervals, and 4 weeks after the last
immunization; animals were subcutaneously infected with
1 × 106 stationary-phase promastigotes of L. amazonensis.
The course of the disease was monitored at weekly
intervals and expressed as the increase in thickness of the
infected footpad compared with the uninfected footpad
(A). The number of parasites in the infected footpads was
also measured (B), 10 weeks after challenge, by a limiting-
dilution technique. Each bar represents the mean ± S.D. of
the diﬀerent groups. (a) indicates statistically signiﬁcant
diﬀerence in relation to the saline group (P < 0·001). (b)
indicates statistically signiﬁcant diﬀerence in relation to
the WTP group (P < 0·001). (c) indicates statistically
signiﬁcant diﬀerence in relation to the NRP group
(P< 0·001).
Fig. 3. Parasite burden in diﬀerent organs of the
immunized animals with B10 and C01 phage clones, and
challenged with Leishmania amazonensis. Mice were
inoculated with saline or immunized with wild-type
(WTP), non-relevant (NRP), B10 or C01 clones (1 × 1011
phages, each one) or with the association between B10 and
C01 clones (5 × 1010 phages, each), with or without 25 μg
of saponin (Quillaja saponaria bark saponin; Sigma-
Aldrich). After the immunization schedules, animals were
infected with 1 × 106 stationary-phase promastigotes of
L. amazonensis, and 10 weeks after challenge, the parasite
burden was determinate in the liver (A), spleen (B), bone
marrow (C) and infected paws’ draining lymph nodes (D),
by a limiting-dilution technique. Each bar represents the
mean ± standard deviation (S.D.) of the diﬀerent groups.
(a) indicates statistically signiﬁcant diﬀerence in relation to
the saline group (P< 0·001). (b) indicates statistically
signiﬁcant diﬀerence in relation to the WTP group (P <
0·001). (c) indicates statistically signiﬁcant diﬀerence in
relation to the NRP group (P< 0·001).
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eﬀectors functions in the spleen of vaccinated and
infected mice; the nitrite concentration was evalu-
ated as an indicator of NO production in the
spleen cell cultures, using either speciﬁc phage- or
SLA-stimulus (Fig. 6B). The nitrite production
was signiﬁcantly higher in mice vaccinated with
the B10, C01, B10/C01 and B10/C01/saponin after
stimulation with phages or SLA, when compared
with the control groups (saline, WTP and NRP).
DISCUSSION
We have recently identiﬁed novel antigens based on a
subtractive phage display strategy, represented by L.
infantummimotopes fused to the phage capsid, which
were strongly reactive against positive sera from VL-
aﬀected dogs and their immunoprotective role was
investigated. The subtraction against sera from non-
infected animals, followed by a positive selection
against asymptomatic and symptomatic VL dogs,
led to the selection of two immunodominant antigens,
represented by the phage clones B10 and C01, which
were successfully employed in the partial protection
of BALB/c mice against L. infantum infection
(Costa et al. 2014). Due to their immunodominance
and protective activity, we hypothesized that such
immunogens could be cross-protective against other
Leishmania spp. species, including those causing
American TL. Interestingly, besides proving that
suchmimotopes could protect againstL. amazonensis,
we also showed that a simple vaccine formulation is
possible just by using the bacteriophage as immuno-
genic carrier, which was able to generate antibodies
against the two recombinant peptides displayed at
the amino terminus of phage coat proteins without
the need of additional adjuvants.
Two experimental controls were used in this study:
the wild-type phage (WTP) and a non-relevant
peptide (NRP) fused to the phage capsid. The WTP
is the same ﬁlamentous bacteriophage derived from
the Ph.D.-C7C Phage Display Peptide Library Kit,
without exogenous peptides fused to the pIII
Fig. 4. Analysis of the cellular response in BALB/c mice after Leishmania amazonensis infection. Mice were inoculated
with saline or immunized with wild-type (WTP), non-relevant (NRP), B10 or C01 clones (1 × 1011 phages, each one), or
with the association between B10 and C01 clones (5 × 1010 phages, each), with or without 25 μg of saponin (Quillaja
saponaria bark saponin; Sigma-Aldrich). Four weeks after the last immunization, animals were subcutaneously infected
with 1 × 106 stationary-phase promastigotes of L. amazonensis, and they were monitored until 10 weeks after challenge.
Then single-cell suspensions were obtained from the spleens of animals, and they were non-stimulated (negative control),
or separately stimulated with SLA (25 μg mL−1), or with the B10, C01, WTP or NRP clones (1 × 1011 phages, each one);
for 48 h at 37 °C in 5%CO2. IFN-γ, IL-12, GM-CSF, IL-4 and IL-10 levels were measured in the culture supernatants by
capture ELISA. Each bar represents the mean ± S.D. of the diﬀerent groups (A). The ratios between the IFN-γ/IL-10 and
IFN-γ/IL-4 levels (B), as well as between the IL-12/IL-10 and IL-12/IL-4 levels (C); are shown. (a) indicates statistically
signiﬁcant diﬀerence in relation to the saline group (P < 0·001). (b) indicates statistically signiﬁcant diﬀerence in relation to
the WTP group (P < 0·001). (c) indicates statistically signiﬁcant diﬀerence in relation to the NRP group (P< 0·001).
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protein. The WTP was used to demonstrate the
speciﬁc immune activation in the host, and how this
could interfere in the target response. The NRP was
used as a mimotope control, in order to verify if the
partial protection induced by clones was due to the
speciﬁc mimotopes. In the results, no protection was
observed in both controls, conﬁrming that the
foreign antigens exposed in the selected phage parti-
cles were the main responsible to partial protection
observed in this study.
Despite the fact that the science behind the treat-
ment of infectious diseases through vaccination was
ﬁrst shown by Edward Jenner more than two centur-
ies ago (Riedel, 2005), and that use of vaccine in
treatment of diseases is widespread now, there are
still problems and limitations in preparing vaccines
by traditional means. The approach used in the
present study can be considered as a new recombin-
ant technology employed to select vaccine candidates
against Leishmania spp. species, and it could be well
considered as a tool to perform other studies aiming
to produce better vaccines against diseases (O’Hagan
and Rappuoli, 2004). In this context, for instance,
the phage display technology has proven to be
useful in selecting antigens based on exposed
foreign peptides on phages, either using their own
clones or their synthetic mimotopes, to be experi-
mentally evaluated to protect against Burkitt’s
lymphoma (Hardy and Raiter, 2005), melanoma
(Wagner et al. 2005), colorectal cancer (Coomber
and Ward, 2001), hepatitis B virus (Wan et al.
2001), VL (Costa et al. 2014) and rotavirus (Van
der Vaart et al. 2006).
Fig. 5. Involvement of CD4+ and CD8+ T cells, as well as
IL-12, in the IFN-γ production after challenge infection.
Single-cells suspensions were obtained from the spleens of
mice that were immunized with B10/C01 (A) or B10/C01/
saponin (B), at 10 weeks after infection. Levels of IFN-γ
were measured in the culture supernatants by capture
ELISA of spleen cells cultures stimulated with SLA (25
μg mL−1), for 48 h at 37 °C in 5% CO2. Cultures were
incubated in the absence (positive control) or in the
presence of 5 μg mL−1 of mAb against mouse IL-12
(C017·8), CD4 (GK 1·5) or mouse CD8 (53–6·7). Each bar
represents the mean ± S.D. of the diﬀerent groups. (a)
indicate statistically signiﬁcant diﬀerences between non-
treated control cells and cultures incubated with anti-
CD4, anti-CD8 or anti-IL-12 mAb (P< 0·001).
Fig. 6. Humoral response and nitrite production in
BALB/c mice after Leishmania amazonensis infection. Sera
samples of the immunized and infected animals were
collected, at 10 weeks after infection. The levels of SLA
L. amazonensis-speciﬁc IgG1 and IgG2a antibodies levels
were determined, and a ratio between the values (IgG2a/
IgG1) was calculated (A). The NO production was also
evaluated in all groups, at 10 weeks after challenge; when
single-cell suspensions were obtained from the spleens of
animals, and they were non-stimulated (negative control),
or separately stimulated with SLA (25 μg mL−1), or with
the B10, C01, WTP or NRP clones (1 × 1011 phages, each
one); for 48 h at 37 °C in 5% CO2. Then, 100 μL of the
individual culture supernatants were mixed with an equal
volume of Griess reagent. After an incubation of 30 min at
room temperature, nitrite concentration was calculated
using a standard curve of known concentrations (B). Each
bar represents the mean ± S.D. of the diﬀerent groups. (a)
indicates statistically signiﬁcant diﬀerence in relation to
the saline group (P< 0·001). (b) indicates statistically
signiﬁcant diﬀerence in relation to the WTP group
(P< 0·001). (c) indicates statistically signiﬁcant diﬀerence
in relation to the NRP group (P < 0·001).
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Whole phage particles possess many intrinsic
characteristics that make them ideal as vaccine deliv-
ery vehicles. Phage vaccines are cheap and can be
easily produced on a large scale. Phages are highly
stable and are even stable within the pH range 3·0–
11·0, over a 24 h period. Because the displayed
protein is fused with a coat protein, it is not suscep-
tible to nuclease degradation under the protective
protein matrix (Gao et al. 2010). The safety issue
of phage vaccine is an important matter and should
be outlined. Phage vaccines have been shown to be
safe in mice (Hashemi et al. 2010), pigs (Gamage
et al. 2009) and humans (Bruttin et al. 2005).
Hence, phages themselves may act as strong adju-
vants and thus enhance excellent immune responses
against any antigens present along with phage
(Frenkel et al. 2000; Manoutcharian et al. 2004).
Additionally, vaccination with phage particles also
induces a highly immunogenic signal against phage
coat protein, which provides an easily detectable
marker to conﬁrm the vaccination eﬀect in animals
(Margonari et al. 2006).
The B10 and C01 phages evaluated in the present
study are expressed fused to pIII proteins of the
phage structure. The minor coat protein pIII is pre-
sented in ﬁve copies per virion, of which all ﬁve can
be fused to short peptides, without interfering in its
infectivity. In contrast, the major coat protein pVIII
is presented as 2700 copies per virion, of which 10%
can be reliably fused to peptides. As a result, pep-
tides expressed as pIII fusions are present at lower
valency, whereas pVIII fusions are present at
higher valency (Gu et al. 2008). Therefore, one
could speculate that the partial protection found
here could be improved by using a construction
based on the hybrid phage fusion of B10 and C01
epitopes to the pVIII molecules from ﬁlamentous
phages. In addition, the incorporation of other im-
munogenic mimotopes could be considered also as
a strategy to develop a phage-displayed multi-
epitope-based vaccine protective to a wider range
of Leishmania spp. species.
There is an emerging trend in experimental vacci-
nology that focuses more on multi-strain or multi-
species rather than strain-speciﬁc vaccines (Hamad,
2011). The concept of universal vaccines is chieﬂy
based on the presence of common antigens among
pathogens and on the ability of properly formulated
vaccines to elicit cross-protective adaptive immun-
ity. Support for antigenic commonality among
pathogens derives from both indirect and direct evi-
dence (Barbour and Restrepo, 2000; Kyes et al.
2007). In this sense, genomics is fast expanding the
list of common proteins among organisms (Pizza
et al. 2000; Kanduc et al. 2008; Real et al. 2013),
and has proven to be useful in selecting common
antigens for vaccine development against diseases,
such as brucellosis (Cherwonogrodzky et al. 2014),
salmonellosis (Heithoﬀ et al. 2015) and encephalitis
(Lobigs and Diamond, 2012). Since multiple
Leishmania spp. species are distributed in the same
or adjacent geographical regions (Duthie et al.
2012), it would be desirable to develop vaccines con-
taining candidates capable of inducing protection
against the infection caused by diﬀerent parasite
species. Thus, to be eﬀective as a human vaccine
against leishmaniasis its components should be
shared by diﬀerent parasite species and, prior to its
use in humans, the protective eﬃcacy of these candi-
dates should be analysed in diﬀerent models of ex-
perimental leishmaniasis (Coelho et al. 2003;
Chávez-Fumagalli et al. 2010; Nico et al. 2014).
In murine leishmaniasis, the development of an
IL-4 or IL-10-mediated immune response inhibits
the protective eﬀects from the IFN-γ response,
which may be well related to the deactivation of
macrophages and the onset of the disease in infected
animals (Gumy et al. 2004). In studies evaluating
vaccine candidates against leishmaniasis, immuno-
gens are usually administered in mice and, after
only a few weeks, they are infected and followed
up for a couple of months. In this time, spleen
cells are collected and cultured in vitro with the anti-
gens used in the immunization process, and/or with
Leishmania spp. extracts, in order to evaluate their
immunogenicity. In this point, cytokines, such as
IFN-γ and IL-12, markers of a Th1 response, and
IL-4 and IL-10, indicators of a Th2 response,
have their levels determined and, together with the
results of the parasite burden, the eﬃcacy of immu-
nogens is evaluated (Martins et al. 2013). Thus, anti-
gens capable of stimulating the development of a
Th1 response, based on the production of high
levels of IFN-γ and IL-12, could be considered a
promising candidate for use against Leishmania
spp. In the present study, the immunization using
the B10 and/or C01 clones was able to induce a
robust and phage-speciﬁc Th1 immune response in
the immunized animals, which was primed by high
levels of IFN-γ, IL-12, combined with the presence
of low levels of IL-4 and IL-10. After infection,
these animals, when compared with the controls, in-
cluding the wild-type and non-relevant clones; dis-
played signiﬁcant reductions in the parasite burden
in the infected footpad, liver, spleen, BM and
dLN, which was correlated with a higher production
of Leishmania-speciﬁc IFN-γ by spleen cells.
Additionally, spleen cells also produced higher
levels of IL-12 and GM-CSF when compared with
the control groups, and GM-CSF is the last cytokine
related to macrophage activation and resistance
in murine models against infection with some
Leishmania spp. species, such as L. infantum
(Chávez-Fumagalli et al. 2010; Costa et al. 2014),
Leishmania major (Dumas et al. 2003) and
Leishmania donovani (Murray et al. 1995). The NO
production was also evaluated in the spleen cell cul-
tures, and showed that the protected animals
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produced higher levels of NO when compared with
the control groups, demonstrating the possible acti-
vation of these cells by a NO-dependent mechanism.
Evaluating the proﬁle of T cells involved on the
IFN-γ production in the protected animals, the
CD8+ T cells proved to be an important source of
IFN-γ in the vaccinated and infected animals.
Depletion of these cells in cultures of spleen cells sti-
mulated with SLA has signiﬁcantly reduced this
production. Although previous reports have shown
that the activation of both CD4+ and CD8+ T cells
subsets may be important for the killing of parasites
in mice vaccinated with diﬀerent parasite recombin-
ant antigens (Pitcovsky et al. 2001; Cunha-Júnior
et al. 2010; Martins et al. 2013), the data of the
present study suggested that CD4+ T cells presented
a lower inﬂuence in the induction of IFN-γ-
mediated response elicited by vaccination with B10
and C01 phage clones. The immunization using iso-
lated B10 and C01 phages induced partial protection
against infection, but the association between clones
was more eﬀective in cross-protect the infected
animals, inducing a more polarized Th1 response
and followed by signiﬁcant reductions in the parasite
load in the infected animals.
This study also demonstrates that the partial pro-
tection of mice against L. amazonensis was associated
with a signiﬁcant reduction of IL-4 and IL-10 levels.
Very low levels of IL-4 and IL-10 were detected
after the stimulation of spleen cells derived from vac-
cinated and infected mice. On the other hand, spleen
cells from control mice showed a signiﬁcantly higher
production of these cytokines. In the evaluation of
the humoral response, usually, in L. amazonensis-
infected BALB/c mice, the IL-4-dependent produc-
tion of IgG1 antibodies is associated with the
progression and severity of disease; whereas IFN-γ
is related to the production of IgG2a isotype, and
with protection against infection (Coelho et al.
2003; Chávez-Fumagalli et al. 2010). Here, immu-
nized mice with phage clones that were protected
against infection presented higher levels of SLA-
speciﬁc IgG2a antibodies, as compared with IgG1
levels; correlating with the development of a Th1
immune response observed in these animals. On
the other hand, animals of the control groups;
which were not protect against infection, showed
high levels of L. amazonensis-speciﬁc IgG1
antibodies.
A limiting condition of the present study could be
considered the fact that immunized animals were not
infected lately of 4 weeks after the last immuniza-
tion. However, others have also showed a partial
protection in their studies evaluating diﬀerent
vaccine candidates against VL or TL, using the
same period of time evaluated in the present study
(Iborra et al. 2008; Chávez-Fumagalli et al. 2010;
Costa et al. 2014; Nico et al. 2014). Clearly, a
vaccine able to induce a long protection would be
desirable, but the main purpose of the present
study was to present mimotopes that were selected
in a viscerotropic Leishmania spp. species as being
able to confer a partial cross-protective eﬃcacy
against a Leishmania spp. species able to causes
American TL. Also, the present study could be con-
sidered a proof-of-concept about the eﬃcacy of these
mimotopes to be employed in a vaccine composition
to protect against VL, once the number of animals
evaluated in each experimental group could be con-
sidered low. However, since the level of cytokines,
the antibody reactivities and the evolution of the
disease have been homogeneous in all the compo-
nents from each analysed group, it could be postu-
lated that the vaccine can be also eﬀective against a
higher evaluated population.
A critical aspect for Leishmania vaccine develop-
ment refers to the pre-clinical model chosen for the
initial screening of vaccine candidates. Although
sand ﬂy transmitted infection in hamsters more
closely resemble the natural transmission and the
human disease, this infection model requires speciﬁc
laboratory conditions and trained personnel staﬀ,
which are not widely available, hindering its general
use as a ﬁrst step for testing vaccine eﬃcacy against
VL (Gomes et al. 2008). In contrast, BALB/c mice
infected with L. donovani or L. infantum is one the
most widely studied murine model of VL, and is
therefore naturally selected over other models for
this purpose (Afrin et al. 2000; Coelho et al. 2003;
Carrión et al. 2006). Murine models have also
allowed the characterization of the immune mechan-
isms required to develop organ-speciﬁc immune re-
sponse against diﬀerent Leishmania spp. species
(Requena et al. 2004). Therefore, the evaluation of
the parasite burden in diﬀerent organs is an important
marker of vaccine eﬃcacy against VL in these models.
Nevertheless, additional studies may well be carried
out in order to extend the observations present
herein of the protective eﬀect of the phage clones vac-
cination to other infection models and experimental
conditions.
In conclusion, we have shown that a simple
vaccine formulation based on phage-fused peptides
could be well used to induce partial protection in
BALB/c mice against L. amazonensis infection.
This eﬀect was correlated by a CD8+ T cells re-
sponse, which was based on the production of high
levels of IFN-γ, IL-12, GM-CSF and NO; as well
as low levels of IL-4, IL-10 and antileishmanial
IgG1-isotype antibodies. The combination of these
phage clones was able to improve the vaccine
eﬃcacy against L. amazonensis, and this result has
led us to the conclusion that these antigens may
be well used as vaccine candidates to, alone or in
combination to other immunogens, be evaluated
against Leishmania spp. infections. Additional
studies are under way in order to identify the
native proteins that express these target mimotopes.
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